Skip to content
value.today

Arno Therapeutics, Inc

Formerly Laurier International, Inc.

Total raised
$55 M
4 rounds on record
Latest round
$5 M
Aug 2016
First round on record
Sep 2010
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Arno Therapeutics, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2016$5 MNo. 4$2 to $10 million

Arno Therapeutics, Inc: Raise no. 4, Aug 2016

Investors in this round

15 investors had bought by the notice of Aug 30, 2016: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander Zukiwski, M.D. · Executive Officer, Director
  • Stefan M. Proniuk, Ph.D. · Executive Officer
  • Arie S. Belldegrun, M.D. · Director
  • David M. Tanen · Director
  • Jay F. Moorin · Director
  • Steven B. Ruchefsky · Director
  • Tomer F. Kariv · Director
  • William F. Hamilton, Ph.D. · Director
  • Yacov F. Reizman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes the amount that may be received upon the future exercise of warrants.”

Signed by Alexander Zukiwski, M.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 30, 2016. Read the notice at the SEC.

equity, optionsSEC
Oct 2013$31 MNo. 3$10 to $50 million

Arno Therapeutics, Inc: Raise no. 3, Oct 2013

Investors in this round

69 investors had bought by the notice of Nov 13, 2013: 69 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander R. Zukiwski, M.D. · Executive Officer
  • Glenn R. Mattes · Executive Officer, Director
  • Scott L. Navins · Executive Officer
  • Stefan L. Proniuk, Ph.D. · Executive Officer
  • Arie S. Belldegrun, M.D. · Director
  • David M. Tanen · Director
  • Randy H. Thurman · Director
  • Steven B. Ruchefsky · Director
  • Tomer L. Kariv · Director
  • William F. Hamilton, Ph.D. · Director
  • Yacov L. Reizman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Glenn R. Mattes, President and CEO. Source: SEC Form D, newest notice filed Nov 13, 2013. Read the notice at the SEC.

equity, optionsSEC
Nov 2012$11 MNo. 2$10 to $50 million

Arno Therapeutics, Inc: Raise no. 2, Nov 2012

Investors in this round

16 investors had bought by the notice of Dec 6, 2012: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $18 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$842,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander R. Zukiwski, M.D. · Executive Officer
  • Glenn R. Mattes · Executive Officer, Director
  • Scott L. Navins · Executive Officer
  • Stefan L. Proniuk, Ph.D. · Executive Officer
  • Arie S. Belldegrun, M.D. · Director
  • David M. Tanen · Director
  • Steven B. Ruchefsky · Director
  • Tomer L. Kariv · Director
  • William F. Hamilton, Ph.D. · Director
  • Yacov L. Reizman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · broker-dealer Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “In addition to a cash fee of $842,500, warrants to purchase 2,090,000 shares were issued, as well as 60,000 shares and reimbursement for out of pocket expenses up to $30,000.”

Signed by David M. Tanen, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Dec 6, 2012. Read the notice at the SEC.

equity, debt, optionsSEC
Sep 2010$8 MNo. 1$2 to $10 million

Arno Therapeutics, Inc: Raise no. 1, Sep 2010

Investors in this round

24 investors had bought by the notice of Sep 23, 2010: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $13 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$925,750
Finders' fees
none
Paid to its own people
$669,200 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Tanen · Executive Officer, Director
  • Arie S. Belldegrun · Director
  • Joshua A. Kazam · Director
  • Peter M. Kash · Director
  • Robert I. Falk · Director
  • William F. Hamilton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • I-Bankers Securities, Inc. (CRD 41352) · broker-dealer I-Bankers Securities, Inc. (CRD 41352) · Santa Monica, CaliforniaSold in CA, CO, CT, DE, FL, GA, IL, MA, MD, MI, NC, NJ, NY, PA, SC, TX, and outside the US
  • Riverbank Capital Securities, Inc. (CRD 135310) · broker-dealer Riverbank Capital Securities, Inc. (CRD 135310) · New York, New YorkSold in AZ, CA, CO, CT, DC, DE, FL, IL, MA, MD, MI, NC, NJ, NY, OH, PA, TN, TX, VA, WA, and outside the US

Remarks in the notice

  • On fees: “Max. commission if entire offering is sold. Warrants will also be issued to purchase shares equal to 7% of the aggregate no. of shares sold. Reasonable out-of-pocket expenses and legal fees will be paid.”
  • On the use of proceeds: “Assumes entire offering is sold; Riverbank commissions may be allocated between Messrs. Kash, Kazam and Tanen.”

Signed by David M. Tanen, President. Source: SEC Form D, newest notice filed Sep 23, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Arno Therapeutics, Inc chose not to state its revenue in its newest notice of a funding round (Aug 2016).

    SEC Form D · Aug 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2016

That is all the official record says: Arno Therapeutics, Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Arno Therapeutics, Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 69 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arno Therapeutics, Inc
NameRoleNamed in
Alexander Zukiwski, M.D.Executive officerAug 2016
Stefan M. Proniuk, Ph.D.Executive officerAug 2016
Alexander R. Zukiwski, M.D.Executive officerNov 2013
Glenn R. MattesExecutive officerNov 2013
Scott L. NavinsExecutive officerNov 2013
Stefan L. Proniuk, Ph.D.Executive officerNov 2013
David M. TanenExecutive officerSep 2010
Alexander Zukiwski, M.D.DirectorAug 2016
Arie S. Belldegrun, M.D.DirectorAug 2016
David M. TanenDirectorAug 2016
Jay F. MoorinDirectorAug 2016
Steven B. RuchefskyDirectorAug 2016
Tomer F. KarivDirectorAug 2016
William F. Hamilton, Ph.D.DirectorAug 2016
Yacov F. ReizmanDirectorAug 2016
Glenn R. MattesDirectorNov 2013
Randy H. ThurmanDirectorNov 2013
Tomer L. KarivDirectorNov 2013
Yacov L. ReizmanDirectorNov 2013
Arie S. BelldegrunDirectorSep 2010
Joshua A. KazamDirectorSep 2010
Peter M. KashDirectorSep 2010
Robert I. FalkDirectorSep 2010
William F. HamiltonDirectorSep 2010